{'fraction_non_alphanumeric': 0.02531645569620253, 'fraction_numerical': 0.009845288326300985, 'mean_word_length': 5.245614035087719, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Revisiting the role of IL‐2 in autoimmunity

IL‐2 was discovered as a T‐cell growth factor that promoted T‐cell‐dependent immune responses; however, more recent studies suggest that the essential role of IL‐2 is to maintain functional Treg and thus control immune responses. These results are leading to new ideas about the potential of IL‐2 as a therapeutic strategy in autoimmune diseases. In this issue of the European Journal of Immunology, a study further examines the role of IL‐2 in immune regulation and shows for the first time that IL‐2 complexes can ameliorate autoantibody‐mediated autoimmunity. This commentary examines the current findings in relation to what we already know about IL‐2 complexes.